Skip to main content
Caplight Logo









BioAegis Therapeutics

BioAegis Therapeutics

Private
New JerseyHealthcare & Life Scienceshttps://www.bioaegistherapeutics.com/

Last Round

Grant

Oct 16, 2023

Total Funding Raised

$50M

Company Overview

BioAegis Therapeutics is a clinical-stage biotechnology company developing therapies for inflammatory, infectious, and degenerative diseases based on its plasma gelsolin (pGSN) platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

recombinant human plasma gelsolinrhu-pGSNplasma gelsolinpGSNclinical-stage biotechAcute Respiratory Distress SyndromeARDShost-directed therapybiologicsnon-immunosuppressive therapyDecompression SicknessDCSanti-inflammatory therapydrug developmentsepsis therapyBARDA contract

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BioAegis Therapeutics Comparables

Compare BioAegis Therapeutics with similar companies based on industry and business-model similarity.

BioAegis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aqualung Therapeutics Corporation
82%
Implicit Bioscience
78%
Trove Therapeutics
77%

BioAegis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 16, 2023
Series CMar 22, 2022
Convertible DebtJun 23, 2020
DebtApr 28, 2020
VC RoundSep 17, 2018
Seed
Feb 8, 2013

Key People

Founding team and executive leadership

Susan Levinson

Chief Executive Officer

Executive Team

BioAegis Therapeutics Investors

Notable investors and investment history

BioAegis Therapeutics investors
InvestorRounds
Public Health Emergency Medical Countermeasures EnterpriseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    Monthly visitors grew 95% MoM, reaching 1.3K.

  • May 2, 2025

    Monthly visitors increased 45% MoM, reaching 1.4K.

BioAegis Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BioAegis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BioAegis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Jersey
Employee Range14
Year Founded2011
Last FundingOct 16, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?